Screening for Roche Alzheimer's studies
Part of Brain & nervous system, Mental health clinical trials.
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You agree to join a longer Alzheimer's study if you qualify
- You can get information about possibly joining another Roche Alzheimer's study
- You do not need help with basic daily tasks (like eating or dressing) because of memory loss
- You do not have another major brain condition (like Parkinson's or a stroke) that affects thinking
- Your hearing and vision are good enough to do thinking tests (glasses and hearing aids are okay)
- No serious medical problems that make a study unsafe for you
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called RO7568282 for people in the early stages of Alzheimer's disease. The goal is to see if it is safe and whether it can slow down memory loss and thinking problems.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This trial is a brief survey to see if you might qualify for future neurology research studies. It helps researchers understand your health and find the right study for you.
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
This study is testing whether simple digital memory tests and blood tests can help find people who might qualify for anti-amyloid treatments (medications that target Alzheimer's-related proteins). It aims to make screening easier and faster, without needing a spinal tap or PET scan.
This study looks for brain/biological “signals” (biomarkers) that may identify Alzheimer’s disease earlier, including stages before clear symptoms. You may be followed for about 5 years, with repeated memory and thinking testing to see how these signs relate to future diagnosis.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.